Penta deca peptide arginate typically costs more per unit than BPC-157 acetate, but the improved oral bioavailability can make it more cost-effective on a per-effective-dose basis for oral protocols
One of the biggest challenges when evaluating BPC-157 safety is the limited availability of large-scale human clinical trials
(7) BPC-157 Peptide and Tissue Damage A study was conducted to understand the extent of the angiogenic potential of the peptide beyond local wounds, ligaments, and GI tract wounds and to study its action on multiple gastrointestinal lesions on the pancreas, liver injuries, heart damage, endothelium damage, and blood pressure
By rapidly recruiting alternative pathways around occluded vessels, BPC-157 addresses the consequences of thrombosis without necessarily dissolving the clot itself
BPC-157 has been studied across gastrointestinal, musculoskeletal, cardiovascular, and neurological models reflecting proposed interactions with multiple signalling systems including the NO pathway, growth factor receptors, and neurotransmitter systems